TRIB1: a multifaceted regulator of cardiometabolic health

Area of Science:

• Biomedical research
• Genetics
• Cardiovascular medicine

Background:

• Cardiovascular diseases (CVDs) are a leading global cause of death, driven by risk factors like dyslipidemia, atherosclerosis, diabetes, and obesity.
• Genome-wide association studies (GWASs) have identified the 8q24 locus, including the TRIB1 gene, associated with cardiometabolic traits.

Purpose of the Study:

• To review the role of Tribbles homolog 1 (Trib1) as a therapeutic biomarker in cardiovascular diseases (CVDs).
• To explore Trib1's association with lipid metabolism, atherosclerosis, obesity, and diabetes.
• To analyze in vitro and in vivo studies and elucidate Trib1's molecular mechanisms in CVD.

Main Methods:

• Literature review of in vitro and in vivo studies.
• Analysis of genome-wide association studies (GWASs) data.
• Exploration of molecular mechanisms underlying Trib1 function.

Main Results:

• Trib1 is linked to key cardiometabolic traits including plasma lipid levels (triglycerides, LDL, HDL, total cholesterol) and glycated hemoglobin.
• Emerging evidence suggests Trib1's involvement in regulating plasma lipid levels, inflammation, and insulin signaling.
• Trib1 presents potential as a novel biomarker for CVD risk assessment.

Conclusions:

• Trib1 plays a crucial role in pathways relevant to cardiovascular health.
• Targeting Trib1 may offer new therapeutic strategies for preventing and managing CVDs.
• Further research into Trib1's mechanisms can enhance CVD risk stratification and treatment.